Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis.

PloS One
Michael A ApicellaBradford W Gibson

Abstract

Capsular polysaccharides are important factors in bacterial pathogenesis and have been the target of a number of successful vaccines. Francisella tularensis has been considered to express a capsular antigen but none has been isolated or characterized. We have developed a monoclonal antibody, 11B7, which recognizes the capsular polysaccharide of F. tularensis migrating on Western blot as a diffuse band between 100 kDa and 250 kDa. The capsule stains poorly on SDS-PAGE with silver stain but can be visualized using ProQ Emerald glycoprotein stain. The capsule appears to be highly conserved among strains of F. tularensis as antibody 11B7 bound to the capsule of 14 of 14 F. tularensis type A and B strains on Western blot. The capsular material can be isolated essentially free of LPS, is phenol and proteinase K resistant, ethanol precipitable and does not dissociate in sodium dodecyl sulfate. Immunoelectron microscopy with colloidal gold demonstrates 11B7 circumferentially staining the surface of F. tularensis which is typical of a polysaccharide capsule. Mass spectrometry, compositional analysis and NMR indicate that the capsule is composed of a polymer of the tetrasaccharide repeat, 4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->3...Continue Reading

References

Aug 1, 1977·The Journal of Hygiene·A M Hood
Dec 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C Rose, W V Kern
Jul 30, 1991·Carbohydrate Research·E V VinogradovV S Khlebnikov
Feb 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A TärnvikG Sandström
Feb 19, 1970·The New England Journal of Medicine·M S ArtensteinC Harkins
Nov 1, 1995·Journal of Biomolecular NMR·F DelaglioA Bax
Mar 1, 1996·FEMS Immunology and Medical Microbiology·V M SorokinL A Prozorova
Jan 1, 1996·Annual Review of Microbiology·I S Roberts
Apr 21, 1998·Nature·L SteeghsP van der Ley
Jun 21, 2001·JAMA : the Journal of the American Medical Association·D T DennisUNKNOWN Working Group on Civilian Biodefense
Mar 20, 2002·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Apr 16, 2002·Internal Medicine Journal·S J Kent
Jan 9, 2003·Expert Opinion on Biological Therapy·Larry I Lutwick, Mary Beth Nierengarten
May 1, 1961·Archives of Internal Medicine·S SASLAWS CARHART
May 1, 1961·Archives of Internal Medicine·S SASLAWS CARHART
Aug 24, 2004·Infection and Immunity·Nancy J PhillipsBradford W Gibson
Dec 3, 2004·Applied and Environmental Microbiology·Tamara M MaierThomas C Zahrt
Jun 11, 2005·Journal of Medical Microbiology·Nagaraja R ThirumalapuraJerry Malayer
Aug 23, 2005·Infection and Immunity·Simon AllenMichael A Apicella
Mar 7, 2006·Applied and Environmental Microbiology·Tamara M MaierD W Frank
Jun 8, 2006·Annual Review of Biochemistry·Chris Whitfield
Apr 11, 2007·Infection and Immunity·Jingliang SuJing-Ren Zhang
Jul 14, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alan S CrossRobert Edelman
Aug 29, 2007·Infection and Immunity·Molly K McLendonBradford W Gibson
Sep 14, 2007·Molecular Plant-microbe Interactions : MPMI·Jeri D BarakAmy O Charkowski

❮ Previous
Next ❯

Citations

Jun 27, 2014·PloS One·Zhaohua LuJacqueline Sharon
Oct 19, 2012·Future Microbiology·Elodie RamondAlain Charbit
Apr 30, 2011·Future Microbiology·J Wayne Conlan
Aug 30, 2014·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Zhaohua LuJacqueline Sharon
Jun 2, 2011·The Journal of Infectious Diseases·Joseph HorzempaGerard J Nau
Aug 2, 2011·Journal of Bacteriology·Rebecca M ThomasJoann L Prior
Jun 13, 2012·Microbiology and Molecular Biology Reviews : MMBR·Crystal L JonesDavid S Weiss
Aug 7, 2013·Carbohydrate Research·Nihal A Okan, Dennis L Kasper
Jul 7, 2012·Analytical and Bioanalytical Chemistry·Gregory A BardingCynthia K Larive
Jan 19, 2016·Frontiers in Cellular and Infection Microbiology·Hannah M Rowe, Jason F Huntley
May 23, 2015·Drug Discoveries & Therapeutics·Guangping LvShaoping Li
Nov 30, 2013·Cellular Microbiology·Elizabeth Di Russo CaseJean Celli
Mar 19, 2014·Frontiers in Cellular and Infection Microbiology·Bradley D JonesJoshua R Fletcher
Jun 9, 2016·Proceedings of the National Academy of Sciences of the United States of America·Linxiao ChenMatthew P DeLisa
Dec 2, 2011·Chemical Society Reviews·Lev Dykman, Nikolai Khlebtsov
Aug 26, 2016·Immunological Reviews·Lauren C Kinkead, Lee-Ann H Allen
Feb 24, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Justin T SchwartzLee-Ann H Allen
Aug 14, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Justin T SchwartzLee-Ann H Allen
Jul 3, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Robin IrelandCatharine M Bosio
Feb 14, 2020·Microbiology and Molecular Biology Reviews : MMBR·Kelly C Freudenberger Catanzaro, Thomas J Inzana
Sep 20, 2020·International Journal of Molecular Sciences·Anna MaciejewskaJolanta Lukasiewicz
Jul 7, 2020·Expert Review of Vaccines·Jennifer Mhairi DowBrendan William Wren
Apr 1, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Elliott V WyattCatharine M Bosio

❮ Previous
Next ❯

Methods Mentioned

BETA
genetic modifications
NMR
ELISA
electron microscopy
scraping

Software Mentioned

R Development Core Team
Sparky
R survival package
NMRPipe
BLAST
R

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.